RaQualia Pharma (TSE:4579) PE Ratio: At Loss (As of Jul. 08, 2026)


TSE:4579 RaQualia Pharma Inc TSE:4579
57 GF Score
Price 円468.00
GF Value 円961.31
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is RaQualia Pharma PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-08), RaQualia Pharma's share price is 円468.00. RaQualia Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-24.09. Therefore, RaQualia Pharma's PE Ratio for today is At Loss.

During the past 13 years, RaQualia Pharma's highest PE Ratio was 145.71. The lowest was 0.00. And the median was 33.78.

RaQualia Pharma's EPS (Diluted) for the three months ended in Mar. 2026 was 円-8.84. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-24.09.

As of today (2026-07-08), RaQualia Pharma's share price is 円468.00. RaQualia Pharma's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was 円-24.14. Therefore, RaQualia Pharma's PE Ratio without NRI ratio for today is At Loss.

During the past 13 years, RaQualia Pharma's highest PE Ratio without NRI was 140.33. The lowest was 0.00. And the median was 32.90.

RaQualia Pharma's EPS without NRI for the three months ended in Mar. 2026 was 円-8.57. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was 円-24.14.

During the past 3 years, the average EPS without NRI Growth Rate was -33.60% per year.

During the past 13 years, RaQualia Pharma's highest 3-Year average EPS without NRI Growth Rate was 92.20% per year. The lowest was -94.60% per year. And the median was 21.60% per year.

RaQualia Pharma's EPS (Basic) for the three months ended in Mar. 2026 was 円-8.84. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-24.09.

Back to Basics: PE Ratio


RaQualia Pharma  (TSE:4579) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


RaQualia Pharma PE Ratio Related Terms


RaQualia Pharma PE Ratio Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma PE Ratio Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.57 35.74 At Loss At Loss 88.91

RaQualia Pharma Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss 88.91 At Loss

TSE:4579 vs VRTX, REGN, ALNY: PE Ratio Comparison

For the Biotechnology subindustry, RaQualia Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RaQualia Pharma PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RaQualia Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where RaQualia Pharma's PE Ratio falls into.


TSE:4579
57GF Score
RaQualia Pharma Inc TSE:4579
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

RaQualia Pharma's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=468.00/-24.090
=-19.43(At Loss)

RaQualia Pharma's Share Price of today is 円468.00.
RaQualia Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-24.09.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31. GuruFocus considers RaQualia Pharma to be Significantly Undervalued.

Key valuation signals for TSE:4579:

  • PE Ratio: At Loss
  • GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score

Get the complete analysis for TSE:4579

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円468.00
Price
円961.31
GF Value